GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zealand Pharma AS (LTS:0NZU) » Definitions » Net Margin %

Zealand Pharma AS (LTS:0NZU) Net Margin % : -6,033.88% (As of Sep. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Zealand Pharma AS Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Zealand Pharma AS's Net Income for the three months ended in Sep. 2024 was kr-266.40 Mil. Zealand Pharma AS's Revenue for the three months ended in Sep. 2024 was kr4.42 Mil. Therefore, Zealand Pharma AS's net margin for the quarter that ended in Sep. 2024 was -6,033.88%.

The historical rank and industry rank for Zealand Pharma AS's Net Margin % or its related term are showing as below:

LTS:0NZU' s Net Margin % Range Over the Past 10 Years
Min: -1382.77   Med: -203.3   Max: 1530.61
Current: -1369.25


LTS:0NZU's Net Margin % is ranked worse than
77.59% of 1013 companies
in the Biotechnology industry
Industry Median: -140.3 vs LTS:0NZU: -1369.25

Zealand Pharma AS Net Margin % Historical Data

The historical data trend for Zealand Pharma AS's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zealand Pharma AS Net Margin % Chart

Zealand Pharma AS Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,382.77 -441.00 -937.99 -1,156.05 -205.30

Zealand Pharma AS Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.09 -1,139.44 -1,515.32 -857.73 -6,033.88

Competitive Comparison of Zealand Pharma AS's Net Margin %

For the Biotechnology subindustry, Zealand Pharma AS's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zealand Pharma AS's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zealand Pharma AS's Net Margin % distribution charts can be found below:

* The bar in red indicates where Zealand Pharma AS's Net Margin % falls into.



Zealand Pharma AS Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Zealand Pharma AS's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin=Net Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-703.739/342.788
=-205.30 %

Zealand Pharma AS's Net Margin for the quarter that ended in Sep. 2024 is calculated as

Net Margin=Net Income (Q: Sep. 2024 )/Revenue (Q: Sep. 2024 )
=-266.396/4.415
=-6,033.88 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zealand Pharma AS  (LTS:0NZU) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Zealand Pharma AS Net Margin % Related Terms

Thank you for viewing the detailed overview of Zealand Pharma AS's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Zealand Pharma AS Business Description

Traded in Other Exchanges
Address
Sydmarken 11, Soborg, DNK, DK-2860
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.

Zealand Pharma AS Headlines

No Headlines